Program
sonrotoclax
Also written as “Sonrotoclax”, “BGB-11417” and “Sonrotoclax Tablet”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Multiple Myeloma · Waldenstrom Macroglobulinemia · Leukemia, Myeloid, Acute, led by BeOne Medicines.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 1613 open or running | phase 3since Oct 3, 2023 | Feb 18, 2020 | Nov 2026phase 2 · NCT04973605 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 18, 2020.
- Feb 23, 2021Phase 2 study in Leukemia, Myeloid, AcuteNCT04771130 · 260 planned · United States, Australia, China and more
- May 7, 2021Phase 1 study in Mature B-cell MalignanciesNCT04883957 · 64 enrolled · China
- Jul 7, 2021Phase 2 study in Multiple MyelomaNCT04973605 · 246 planned · United States, Australia, Brazil and more
- Jul 21, 20222 phase 2 studiesNCT05471843, NCT05479994
- Apr 25, 2023Phase 1 study in Healthy VolunteersNCT05844111 · 6 enrolled · United States
- Jul 11, 2023Phase 2 study in Waldenstrom MacroglobulinemiaNCT05952037 · 114 enrolled · United States, Australia, Canada and more
- Oct 3, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06073821 · 652 enrolled · United States, Australia, Austria and more
- Oct 9, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06637501 · 94 enrolled · United States, Brazil, China and more
- Nov 18, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06697184 · 258 planned · United States, Australia, Brazil and more
- Dec 16, 2024Phase 3 study in Lymphoma, Mantle-CellNCT06742996 · 300 planned · United States, Argentina, Australia and more
- Apr 17, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06943872 · 630 planned · United States, Argentina, Australia and more
- Dec 2, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07277231 · 500 planned · United States, Australia, Brazil and more
- May 22, 2026Phase 1 study in Healthy VolunteersNCT07628881 · 12 enrolled · Australia
- Sep 29, 2026Phase 1 study in Hepatic ImpairmentNCT07855991 · 12 planned
Ahead
- Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06637501
- Nov 2026Primary completion: phase 2 study in Multiple MyelomaNCT04973605
- Feb 8, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07855991
- May 31, 2027Primary completion: phase 1 study in Mature B-Cell MalignanciesNCT04277637
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07855991Hepatic Impairment | 1 | Not yet recruiting | Feb 8, 2027 | 12 |
| NCT07628881Healthy Volunteers · Australia | 1 | Completed | Sep 26, 2026 | 12 |
| NCT07277231Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 3 | Recruiting | Feb 2031 | 500 |
| NCT06943872Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Recruiting | Sep 30, 2029 | 630 |
| NCT06742996Lymphoma, Mantle-Cell · United States, Argentina, Australia and more | 3 | Recruiting | Aug 31, 2028 | 300 |
| NCT06697184Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 2 | Recruiting | Nov 30, 2029 | 258 |
| NCT06637501Leukemia, Lymphocytic, Chronic, B-Cell · United States, Brazil, China and more | 2 | Active, not recruiting | Nov 2026 | 94 |
| NCT06073821Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Feb 2032 | 652 |
| NCT05952037Waldenstrom Macroglobulinemia · United States, Australia, Canada and more | 2 | Active, not recruiting | Sep 22, 2026 | 114 |
| NCT05844111Healthy Volunteers · United States | 1 | Completed | Jun 18, 2023 | 6 |
| NCT05479994Leukemia · China | 2 | Active, not recruiting | Jan 24, 2025 | 100 |
| NCT05471843Lymphoma, Mantle-Cell · United States, Argentina, Belgium and more | 2 | Active, not recruiting | Jul 18, 2025 | 125 |
| NCT04973605Multiple Myeloma · United States, Australia, Brazil and more | 2 | Recruiting | Nov 2026 | 246 |
| NCT04883957Mature B-cell Malignancies · China | 1 | Completed | Sep 1, 2026 | 64 |
| NCT04771130Leukemia, Myeloid, Acute · United States, Australia, China and more | 2 | Recruiting | Aug 31, 2028 | 260 |
| NCT04277637Mature B-Cell Malignancies · United States, Australia, Germany and more | 1 | Active, not recruiting | May 31, 2027 | 437 |
How it is read
Names in the registry
- “Sonrotoclax”, 11 entries
- “BGB-11417”, 5 entries
- “Sonrotoclax Tablet”, 1 entry
- “[14C]-BGB-11417”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 6 studies
- Lymphoma, Mantle-Cell, 2 studies
- Multiple Myeloma, 1 study
- Waldenstrom Macroglobulinemia, 1 study
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.